TRex Bio Leads 2 Drugmakers Pricing IPOs Totaling $162M
By Jade Martinez-Pogue · October 9, 2026, 8:53 PM EDT
Two clinical-stage biotechnology firms, TRex Bio and Retension Pharmaceuticals, hit the public markets on Friday after raising a combined $162 million in their initial public offerings....
To view the full article, register now.